September 24, 2026 Persevere Therapeutics Announces Treatment of First Patient in its MIROC-1 Phase 2a Ovarian Cancer Clinical Trial
March 3, 2026 Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing
